Navigation Links
ADHD Drugs Help Boost Children's Grades
Date:9/21/2007

Study finds better reading, less absenteeism with long-term treatment

FRIDAY, Sept. 21 (HealthDay News) -- Children with attention-deficit/hyperactivity disorder (ADHD) can perform better at school if placed on long-term drug therapy, a new study suggests.

"This is the first study that shows that taking stimulants for ADHD improves long-term school performance," said lead researcher Dr. William Barbaresi, a pediatrician at the Mayo Clinic in Rochester, Minn. "This includes reading achievement, being absent from school and being retained in a grade -- stimulant treatment was associated with better outcomes," he said.

Based on the findings, stimulant medication needs to be considered for every child with ADHD, Barbaresi believes.

"We can make that recommendation now on the basis of long-term improvement in the ways children's lives turn out, not just on the desire to control ADHD behavior symptoms," he said.

A companion study by the same group of researchers finds that children with ADHD are at heightened risk of lowered reading scores, absenteeism, repeating a grade, and dropping out of school.

Both papers are published in the September edition of the Journal of Development & Behavioral Pediatrics.

Experts estimate that in the United States almost 2 million children -- or about 3 percent to 5 percent of young children in the country -- have ADHD. ADHD affects a child's ability to focus and to control impulsive behaviors.

In the first study, Barbaresi's team followed more than 5,700 children from birth until they were 18 years old. Among these children, 277 boys and 93 girls were diagnosed with ADHD.

The Mayo team found that treatment with prescription stimulants, such as Ritalin, was associated with improved long-term academic success of children with ADHD.

Children taking stimulants usually began taking them in elementary school and continued on the medication for almost three years -- about 30.4 months.

By age 13, those taking medication had improved reading scores compared with children with ADHD who didn't receive the drugs, the researchers found. Furthermore, those children taking the highest doses had the most improved reading scores, Barbaresi's group added.

Children treated with medication also were less likely to be absent from school, and the longer they took the drugs, the less absenteeism was seen. In addition, children with ADHD who received stimulants were 1.8 times less likely to be held back a grade than children with ADHD who were not receiving the treatment.

In the second study, Barbaresi's team found that school outcomes for the average child with ADHD were significantly worse compared with children without the condition.

"Reading tests among children with ADHD are almost 30 points lower, children with ADHD are absent for a significantly greater number of days, and children with ADHD are almost three times more likely to drop out of school and be retained a grade," Barbaresi said.

These poor outcomes were equally likely for boys and girls with ADHD, Barbaresi said.

"We can't simply focus on the symptoms of ADHD," Barbaresi said. "We really need to be focusing on the risk for poor outcomes in school and in other aspects of the child's life," he said. "That's why we have to recognize these children and make sure they get appropriate treatment."

The studies were funded by grants from the U.S. Public Health Service, the U.S. National Institutes of Health, the Mayo Clinic, and McNeil Consumer and Specialty Pharmaceuticals, maker of the ADHD stimulant Concerta.

One expert hailed the findings.

"This study reinforces the value and long-term benefit of treatment with stimulant medication," said Dr. Andrew Adesman, chief of developmental and behavioral pediatrics at Schneider Children's Hospital in New York City. "It also highlights the risks that ADHD patients face and indicates that those risks can be mitigated by effective treatment," he said.

Another expert had a more mixed reaction to the studies.

"This study provides reassuring evidence that medication is not just blunting hyperactivity or enhancing alertness but actually doing so in a way that protects the capacity to learn," noted Dr. David Katz, director of the Prevention Research Center at Yale University School of Medicine in New Haven, Conn.

But drugs may not be the total answer, he added.

"Ritalin works but is not a desirable alternative to recess, which could perhaps work, too, in some cases at least," Katz said. "We need more attention to the underlying reasons for the rising prevalence of ADHD. Is it lack of physical activity; the highly processed modern diet; the over-stimulation of a multimedia environment; or all of the above?" he wondered.

More information

For more on ADHD, visit the U.S. National Institute of Mental Health.



SOURCES: William Barbaresi, M.D., pediatrician, Mayo Clinic Rochester, Minn.; Andrew Adesman, M.D., chief, developmental and behavioral pediatrics, Schneider Children's Hospital, New York City; David L. Katz, director, Prevention Research Center, Yale University School of Medicine, New Haven, Conn.; September 2007, Journal of Development & Behavioral Pediatrics


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Lean Protein Could Be Key to Obesity Drugs
2. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
3. Nasal Spray Could Take Drugs Direct to Brain.
4. Cancer drugs in development nearly doubled since 1995
5. Cipla holds talks with mining giant to supply AIDS drugs for South African workers
6. African HIV strains more resistant to anti HIV drugs
7. Emphasis to ban Drugs ads by Doctors
8. Drugs said to Reduce HIV Transmission to Baby
9. Cholesterol Drugs Prevent Breast Cancer
10. Risky Drugs To Be Avoided In The Elderly
11. Side Effects Of Some Common Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., ... From Not to Hot,” which will begin airing on February 24, 2017. The show ... from the 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier series ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, ... symposium on “Doping in Sport: How the Culture Might Change,” in ... LLP. The symposium will be held at Pepperdine University in Malibu, California. , ...
(Date:2/23/2017)... ... 2017 , ... Current Meditation , a new meditation ... the U.S. starting this spring. Current Meditation focuses on “meditation for the modern ... Meditation will be the first meditation concept in the U.S. offering franchising opportunities, ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... CALNOC, the ... FACMPE, FACPE, will keynote their upcoming conference – Empowerment, Value and Collaboration – in ... chairman and CEO of the Virginia Mason Health System in Seattle since 2000. In ...
(Date:2/23/2017)... ... 2017 , ... Thomas Vas-Don suffered from severe injury due to ... able to successfully recover. In “ Origin & Insertion Charts for Massage Therapists ” ... principals of massage, anatomy , trigger points and referral pain patterns . ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017 ... gives comprehensive insights on the various drugs ... The report covers all the drugs that ... Preclinical & Clinical). The pipeline focuses on ... small molecules, antibodies, stem cell therapies, recombinant ...
(Date:2/24/2017)... STOCKHOLM , Feb 24, 2017 ... Nomination Committee,s proposal for a new Board of Directors ... Meeting. The 2016-2017 Nomination Committee comprises representatives of the ... third quarter of 2016 who have accepted a seat ... Board. The composition of the 2016-2017 Nomination Committee was ...
(Date:2/24/2017)... 2017 Research and Markets has announced the ... - 2016" report to their offering. ... The latest research Urinary Incontinence Drugs ... benchmarks in the global Urinary Incontinence market. The research answers ... key drugs marketed for Urinary Incontinence and their clinical attributes? How ...
Breaking Medicine Technology: